We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Eurotrol Presents the Future of Blood Gas Controls at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022
Print article
Image: CueSee Ringe - the future of blood gas controls (Photo courtesy of Eurotrol)
Image: CueSee Ringe - the future of blood gas controls (Photo courtesy of Eurotrol)

Eurotrol, Inc. (Elizabethtown, KY, USA) is demonstrating its innovative, patented packaging concept that will modernize the in vitro diagnostic market at MEDICA 2022 Trade Fair being held in Düsseldorf, Germany from 14-17th November.

Eurotrol’s CueSee Ringe is being touted as the future of blood gas controls. A special glass ampoule is sealed inside the CueSee Ringe device. This ampoule breaks with a simple turning motion without the risk of cutting fingers on glass particles or coming into contact with the liquid. After this activation step, the CueSee Ringe functions identically to a standard syringe. The liquid inside the ampoule is not deteriorated by environmental contamination, which reduces pre-analytical errors. This concept is ideal for solutions typically stored in ampoules for quality control, calibration verification, proficiency testing, competency assessment, method validations, and lot comparisons.

At MEDICA 2022, Eurotrol is also demonstrating a breakthrough product, the CueSee CO-OX. Co-oximetry determines the levels of the various derivatives of hemoglobin (Hb) in a patient’s blood. Being able to accurately detect and measure the amount of oxyhemoglobin available to carry O2 to the cells of the body is essential, as well as measurements of the abnormal Hb derivatives: carboxyhemoglobin and methemoglobin. It is crucial that co-oximetry testing for these fractions are validated and proven to measure all, at normal and abnormal levels. CueSee CO-OX has proven performance to help meet everyone’s needs. Eurotrol has revolutionized quality control for CO-oximeters by developing CueSee CO-OX with real hemoglobin derivatives performing like patient samples. Packaged in the ACU-Drop II, this dual-chambered device keeps the oxyhemoglobin separated from the methemoglobin to provide a long shelf-life.

Related Links:
Eurotrol, Inc.

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The new tests seek to detect mutant DNA in blood samples, indicating the presence of cancer cells (Photo courtesy of Christian Stolte/Weill Cornell)

Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods

Liquid biopsy technology has yet to fully deliver on its significant potential. Traditional methods have focused on a narrow range of cancer-associated mutations that are often present in such low quantities... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics